Hims & Hers Reports Q1 Net Loss and Lower EBITDA, Raises Full-Year Revenue Guidance Amid GLP-1 Pivot
Summary
Hims & Hers Health reported a Q1 net loss and lower Adjusted EBITDA, but raised its full-year revenue guidance, emphasizing its strategic pivot into branded GLP-1 products.
Key Events
-
Q1 2026 Financial Performance
The company reported Q1 2026 revenue of $608.1 million, a 4% increase year-over-year. However, it swung to a net loss of $92.1 million from a net income of $49.5 million in Q1 2025, and Adjusted EBITDA declined significantly to $44.3 million from $91.1 million.
-
Full-Year 2026 Guidance Raised for Revenue
Hims & Hers raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion. Full-year Adjusted EBITDA guidance was updated to a range of $275 million to $350 million.
-
Strategic Pivot to Branded GLP-1 Products
Management highlighted a strategic pivot to expand its assortment of branded GLP-1 products, noting early demand signals show meaningful consumer reach broadening. This follows recent news and an 8-K filing on March 11, 2026, regarding a collaboration with Novo Nordisk.
-
Subscriber Growth Continues
Subscribers grew to nearly 2.6 million in Q1 2026, representing a 9% increase year-over-year, indicating continued customer acquisition despite profitability challenges.
Analysis
Hims & Hers Health reported a significant shift to a net loss and a substantial decline in Adjusted EBITDA for Q1 2026 compared to the prior year. This profitability hit is a key concern for investors. However, the company simultaneously raised its full-year revenue guidance, projecting accelerated growth, and highlighted its strategic expansion into branded GLP-1 products. This indicates a trade-off where current profitability is impacted by investments and strategic shifts, but management expects stronger top-line growth in the future, particularly from the high-demand GLP-1 market. Investors will be weighing the immediate profitability challenges against the positive revenue outlook and strategic direction.
At the time of this filing, HIMS was trading at $26.30 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $13.74 to $70.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.